View Older Stories View More Recent Stories

Jul 1, 2024 06:45AM Merck to Hold Second-Quarter 2024 Sales and Earnings Conference Call July 30
Jun 28, 2024 06:53AM Merck Receives Positive EU CHMP Opinion for WINREVAIR™ (sotatercept) in Pulmonary Arterial Hypertension (PAH)
Jun 27, 2024 08:18PM CDC’S ACIP Unanimously Recommends Merck’s CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) for Pneumococcal Vaccination in Appropriate Adults
Jun 26, 2024 07:45PM Patritumab Deruxtecan BLA Submission Receives Complete Response Letter from FDA Due to Inspection Findings at Third-Party Manufacturer
Jun 25, 2024 04:05PM USDA Approves Merck Animal Health’s NOBIVAC® NXT Canine Flu H3N2 – The First and Only RNA-Particle Technology Vaccine for Canine Influenza
Jun 20, 2024 10:00AM Pancreatic Cancer Market Is Projecting to Expand As NCI-Funded Research Expects to Empower Market Growth
Jun 18, 2024 08:00AM MilliporeSigma and The Michael J. Fox Foundation Offer Service to Advance Parkinson’s Research
Jun 17, 2024 05:29PM U.S. FDA Approves CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) for Prevention of Invasive Pneumococcal Disease and Pneumococcal Pneumonia in Adults
Jun 17, 2024 05:15PM Merck (MRK) Announces FDA Approval of KEYTRUDA Plus Carboplatin and Paclitaxel as Treatment for Adult Patients With Primary Advanced or Recurrent Endometrial Carcinoma
Jun 17, 2024 05:15PM FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Carboplatin and Paclitaxel as Treatment for Adult Patients With Primary Advanced or Recurrent Endometrial Carcinoma
Jun 5, 2024 06:45AM Merck to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
Jun 4, 2024 08:00AM MilliporeSigma Announces Siren Biotechnology as Winner of its North American Advance Biotech Grant
May 29, 2024 07:17AM Merck (MRK): FDA Grants Priority Review to Application for KEYTRUDA Plus Chemo as First-Line Treatment of Patients With Malignant Mesothelioma
May 29, 2024 07:15AM FDA Grants Priority Review to Merck’s Application for KEYTRUDA® (pembrolizumab) Plus Chemotherapy as First-Line Treatment of Patients With Unresectable Advanced or Metastatic Malignant Pleural Meso
May 29, 2024 07:02AM Jeito Capital announces the acquisition by Merck & Co (NYSE: MRK) of its portfolio company EyeBio for a potential value of $3 billion
May 29, 2024 06:45AM Merck (MRK) to Acquire EyeBio for Up to $3B
May 29, 2024 06:45AM Merck to Acquire EyeBio
May 28, 2024 03:12PM Merck Announces Third-Quarter 2024 Dividend
May 28, 2024 10:04AM MilliporeSigma Launches First Software for Complete Data Traceability in Microbial Quality Control
May 28, 2024 06:46AM Merck (MRK) Announces Phase 3 KEYNOTE-522 Trial Met its Overall Survival (OS) Endpoint
May 28, 2024 06:45AM Merck Announces Phase 3 KEYNOTE-522 Trial Met its Overall Survival (OS) Endpoint in Patients With High-Risk Early-Stage Triple Negative Breast Cancer (TNBC)
May 22, 2024 01:35PM MilliporeSigma Signs Definitive Agreement to Acquire Mirus Bio, Furthering Ambition to Be a Leading Supplier for Viral Vector Manufacturing
May 15, 2024 06:45AM Merck to Present New Data at 2024 ASCO Annual Meeting Demonstrating Advancements in Novel Oncology Treatment Approaches Across Broad Portfolio and Diverse Pipeline
May 13, 2024 06:47AM Merck (MRK) Provides Update on Phase 3 KeyVibe-010 Trial Evaluating an Investigational Coformulation of Vibostolimab and Pembrolizumab
May 13, 2024 06:45AM Merck Provides Update on Phase 3 KeyVibe-010 Trial Evaluating an Investigational Coformulation of Vibostolimab and Pembrolizumab as Adjuvant Treatment for Patients With Resected High-Risk Melanoma
May 9, 2024 06:46AM Merck (MRK) Provides Update on Phase 3 KEYNOTE-B21 Trial of KEYTRUDA Plus Chemotherapy, With or Without Radiotherapy, for Patients With Newly Diagnosed, High-Risk Endometrial Cancer After Surgery With
May 9, 2024 06:45AM Merck Provides Update on Phase 3 KEYNOTE-B21 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus Chemotherapy, With or Without Radiotherapy, for Patients With Newly Diagnosed, High-Risk Endometrial Cance
May 8, 2024 09:15AM Merck Expands Access to High-Quality Maternal Care for More Than 30 Million Women Worldwide Through Merck for Mothers
May 8, 2024 09:15AM Merck Expands Access to High-Quality Maternal Care for More Than 30 Million Women Worldwide Through Merck for Mothers
May 8, 2024 08:30AM Mitigating Muscle Loss Becoming More Vital, Global Cancer Cachexia Market Projected to Reach $3.3 Billion in 2024
May 8, 2024 06:45AM Merck to Participate in the Bank of America Securities 2024 Healthcare Conference
May 7, 2024 04:00PM Ligand Reports First Quarter 2024 Financial Results
May 1, 2024 07:16AM Merck (MRK) Reports Phase 3 KEYNOTE-811 Trial Met Dual Primary Endpoint of Overall Survival
May 1, 2024 07:15AM Merck Announces Phase 3 KEYNOTE-811 Trial Met Dual Primary Endpoint of Overall Survival (OS) as First-Line Treatment in Patients With HER2-Positive Advanced Gastric or Gastroesophageal Junction (GEJ)
Apr 29, 2024 09:01AM Merck (MRK) Announces Positive Data for V116, an Investigational, 21-Valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults
Apr 29, 2024 09:00AM Merck Announces Positive Data for V116, an Investigational, 21-Valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults
Apr 25, 2024 06:30AM Merck Announces First-Quarter 2024 Financial Results
Apr 17, 2024 08:00AM MilliporeSigma Inspires Students to Explore STEM Careers with 2024 Curiosity Cube Tour
Apr 16, 2024 08:00AM MilliporeSigma Launches First All-in-One Genetic Stability Assay to Accelerate Biosafety Testing
Apr 4, 2024 06:45AM Merck (MRK) Initiates Phase 3 Clinical Trial of MK-1084
Apr 4, 2024 06:45AM Merck Initiates Phase 3 Clinical Trial of MK-1084, an Investigational Oral KRAS G12C Inhibitor, in Combination with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Certain Patients With Metasta
Apr 3, 2024 08:04AM Daiichi Sankyo and Merck (MRK) Announce REJOICE-Ovarian01 Phase 2/3 Trial of Raludotatug Deruxtecan Initiated in Patients with Platinum-Resistant Ovarian Cancer
Apr 3, 2024 08:00AM REJOICE-Ovarian01 Phase 2/3 Trial of Raludotatug Deruxtecan Initiated in Patients with Platinum-Resistant Ovarian Cancer
Apr 1, 2024 06:45AM Merck to Hold First-Quarter 2024 Sales and Earnings Conference Call April 25
Mar 28, 2024 06:46AM Merck (MRK) Announces EU Approval of KEYTRUDA Plus Chemotherapy for NSCLC
Mar 28, 2024 06:45AM European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy as Neoadjuvant Treatment, Then Continued as Monotherapy as Adjuvant Treatment, for Resectable Non-Small Cell Lung Ca
Mar 26, 2024 06:21PM FDA Approves Merck’s WINREVAIR™ (sotatercept-csrk), a First-in-Class Treatment for Adults with Pulmonary Arterial Hypertension (PAH, WHO* Group 1)
Mar 21, 2024 06:45AM Merck (MRK) Provides Update on Phase 3 KEYLYNK-006 Trial of KEYTRUDA Plus Maintenance LYNPARZA
Mar 21, 2024 06:45AM Merck Provides Update on Phase 3 KEYLYNK-006 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus Maintenance LYNPARZA® (olaparib) for Certain Patients With Metastatic Nonsquamous Non-Small Cell Lung Can
Mar 20, 2024 11:03AM MilliporeSigma Invests More than € 300 Million in New Life Science Production Site in Korea
View More Recent Stories View Older Stories